EGS Healthcare Capital Partners
VC Fund
Norwalk, United States
EGS Healthcare Capital Partners is a healthcare private equity firm that invests in late stage private and emerging public healthcare companies with promising commercial products that are either on the market or in late stages of development. The Principals of the firm presently manage two funds with combined committed capital of more than $135million.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries EGS Healthcare Capital Partners invests in
Stages EGS Healthcare Capital Partners invests in
Countries EGS Healthcare Capital Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Stefano Ciampolini
|
|||
Investment Focus
Industry
- Medical 5 (83%)
- Health Care 5 (83%)
- Medical Device 3 (50%)
- Biotechnology 2 (33%)
- Genetics 1 (17%)
Stage
- Series B 3 (50%)
- Series A 1 (17%)
- Series C 1 (17%)
- Funding Round 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Stefano Ciampolini
Founder
|
Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
EKOS Corporation
|
EKOS Corporation pioneered the development and the clinical application of ultrasound accelerated thrombolysis, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists and vascular surgeons at leading institutions around the world use the EKOS EkoSonic Endovascular System toprovide faster, safer and more complete dissolution of thrombus. | $26M / Series C / Mar 21, 2006 | |
Cerexa Inc.
|
Cerexa is a biopharmaceutical company focused on the development of a portfolio of novel anti-infective therapies for the treatment of serious and life-threatening infections. The company’s product portfolio includes Ceftaroline AcetateCeftaroline, an injectable cephalosporin that is used for the treatment of bacterial infections caused bygram-positive and gram-negative pathogens. | $50M / Series A / Aug 23, 2005 | |
Endius
|
Endius was founded in 1997 to provide less traumatic and more effective surgery for the of patients treated for back pain. The company develops invasive and endoscopic spine surgery products and implants and is committed to developing total spine surgery solutions. The company's products include the Atavi system, the TiTLE, and the MDSmicrodebrider system.Endius is acquired by Zimmer Biomet Holdings. | $15M / May 23, 2005 | |
Alveolus
|
Alveolus is a leader in the emerging field of non-vascular interventional stenting through next generation stent technology. | $10M / Series B / Jul 30, 2004 | |
Ardais Corporation
|
Ardais Corporation is a clinical genomics company, is dedicated to enhancing and accelerating biomedical research by introducing actual human disease into the pharmaceutical discovery research process. To achieve its goals, Ardais has incorporated multi-disciplinary scientific expertise into its operations, including pathology, molecular biologyand genomics, statistical genomics, bioinformatics and medical informatics, as well as process management skills such as logistics, industrial engineering, and robotics. The result of this unique integration is a state-of-the-art, proprietary discovery platform that is dramatically transforming genomic research and leading the way to novel diagnostic and therapeutic solutions. | $33.5M / Series B / Mar 20, 2001 | |
|
CytoLogix
|
CytoLogix is a private company that focuses on developing laboratory instrumentation for non-routine complex stains. The company develops the Artisan, a tissue staining instrument used primarily for cancer diagnosis. It claims that the instrument was the first instrument to provide true walk-away automation for both immunohistochemical and complexspecial stains. | $27.4M / Series B / Jan 29, 2001 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does EGS Healthcare Capital Partners invest in?
EGS Healthcare Capital Partners invests primarily in Medical, Health Care and Medical Device startups, most often at Series B and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact EGS Healthcare Capital Partners?
Public channels for EGS Healthcare Capital Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at EGS Healthcare Capital Partners?
The team at EGS Healthcare Capital Partners includes Stefano Ciampolini (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
